ESTRO 2023 - Abstract Book

S206

Saturday 13 May

ESTRO 2023

Oncology, Negrar-Verona, Italy; 8 University of Turin, Radiation Oncology, Turin, Italy; 9 IRCCS IEO European Institute of Oncology, Radiation Oncology, Milan, Italy; 10 Radboud University Medical Center Nijmegen, Radiation Oncology, Nijmegen, The Netherlands; 11 Institute of Oncology, Radiation Oncology, Ljubljana, Slovenia; 12 Medical University of Vienna, Radiation Oncology, Vienna, Austria; 13 Cliniques universitaires Saint-Luc, Radiation Oncology, Saint-Luc, Belgium; 14 Onze-Lieve-Vrouwziekenhuis, Radiation Oncology, Aalst, Belgium; 15 UZ Leuven, Radiation Oncology, Leuven, Belgium; 16 Iridium Netwerk, Wilrijk, Radiation Oncology, Antwerp, Belgium; 17 University Hospital Hradec Kralove, Radiation Oncology, Hradec Kralove, Czech Republic; 18 Campus Bio-Medico University, Radiation Oncology, Rome, Italy; 19 Istituti Clinici Scientifici Maugeri, IRCCS, Radiation Oncology, Pavia, Italy; 20 Vall d'Hebron University Hospital, Radiation Oncology, Barcelona, Spain; 21 Hospital Universitario de La Princesa, Radiation Oncology, Madrid, Spain; 22 Hospital Universitario Reina Sofia, Radiation Oncology, Cordoba, Spain; 23 Istituto Oncologico della Svizzera Italiana, Radiation Oncology, Bellinzona, Switzerland; 24 Hôpital Valais, Radiation Oncology, Sion, Switzerland; 25 University Hospital and University of Bern, Radiation Oncology, Bern, Switzerland; 26 Service Radio-Oncologie Neuchâtel Hôpital Network, Radiation Oncology, La Chaux-de-Fonds, Switzerland; 27 Cantonal Hospital Graubünden, Radiation Oncology, Chur, Switzerland; 28 Aberdeen Royal Infirmary, Radiation Oncology, Aberdeen, United Kingdom; 29 Catharina Hospital, Radiation Oncology, Eindhoven, The Netherlands; 30 Santa Lucia General University Hospital, Radiation Oncology, Cartagena, Spain; 31 GasthuisZusters Antwerpen, Medical Oncology, Antwerpen, Belgium; 32 The Royal Marsden, Medical Oncology, London, United Kingdom; 33 Iridium Network, GZA Ziekenhuizen, Radiation Oncology, Antwerp, Belgium Purpose or Objective SBRT for patients with (oligo-)metastatic cancer receiving targeted- or immunotherapy (TT/IT) has become a frequently practiced and guideline-supported treatment strategy. Our systematic review and consequential consensus process aimed at providing guidance for safe practice of SBRT concurrent with TT/IT patients with metastatic cancer. Materials and Methods A systematic literature review was performed to identify the toxicity profiles of combined SBRT and TT/IT. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts, who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was searched on risk mitigation strategies, the potential need and length of interrupting TT/IT around SBRT delivery, and potential adaptations of radiation dose and fractionation when metastases- directed SBRT is combined with TT/IT.

Results The systematic review identified most evidence for immune checkpoint inhibitors (43%), multikinase inhibitors (23%) and EGFR-inhibitors (19%), whereas no evidence was available for almost all other small molecules (SMs) and Her2 antibodies